AstraZeneca plc (AZN) ORD USD0.25
42.00p
(0.29%)
- Add to watchlist
- Create an alert
- This stock can be held in a
42.00p
(0.29%)
Deal for just £6.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
42.00p
(0.29%)
Deal for just £6.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
AstraZeneca's Calquence leukaemia treatment gets US FDA approval
20 February 2026 10:40
(Sharecast News) - AstraZeneca said on Friday that the US Food and Drug Administration has approved its 'Calquence', or acalabrutinib, in combination with venetoclax as the first all-oral,...
-
Shore Capital lowers AstraZeneca to 'hold'
13 February 2026 13:59
(Sharecast News) - Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's nearterm earnings outlook looked less favourable despite...
-
Annual sales, profits jump at AstraZeneca
10 February 2026 07:29
(Sharecast News) - AstraZeneca posted a spike in full-year revenues and earnings on Tuesday, boosted by strong demand for its cancer drugs, and forecast further growth in the current year.
-
FDA rejects self-injectable version of AstraZeneca lupus drug
3 February 2026 07:34
(Sharecast News) - The US health regulator has rejected an application by AstraZeneca to launch a self-injectable version of its lupus treatment Saphnelo, the drugs giant confirmed on Tuesday.
-
Astrazeneca's Imfinzi receives EU recommendation from CHMP
2 February 2026 07:29
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its gastric and gastroesophageal junction cancer treatment, Imfinzi, has been recommended for approval in the European Union by the Committee for...
-
AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals
30 January 2026 07:03
(Sharecast News) - Drugmaker Astrazeneca said on Friday that it has expanded its weightmanagement pipeline after striking a strategic collaboration with CSPC Pharmaceuticals to develop a series of...
-
AstraZeneca unveils $15bn China investment
29 January 2026 07:37
(Sharecast News) - AstraZeneca is to invest $15bn in China by the end of the decade, the UK drugs giant confirmed on Thursday, as part of the prime minister's visit to the country.
-
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27 January 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
-
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles
22 December 2025 08:52
(Sharecast News) - AstraZeneca on Monday reported mixed regulatory and clinical news, with its breast cancer drug Enhertu securing a US breakthrough therapy designation in early disease, while a late-stage...
-
AstraZeneca chalks up dual regulatory wins in cancer and immunology
16 December 2025 07:42
(Sharecast News) - Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.
-
AstraZeneca secures US approval for Imfinzi in gastric cancer
26 November 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT chemotherapy in the treatment of adult patients with resectable,...
-
AstraZeneca to spend $2bn in US manufacturing push
24 November 2025 07:01
(Sharecast News) - AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on Monday.
Company announcements Announcements
-
Notice of AGM
10 March 2026 11:00
AstraZeneca
-
Director/PDMR Shareholding
6 March 2026 11:10
AstraZeneca
-
Director/PDMR Shareholding
6 March 2026 11:05
AstraZeneca
-
Director/PDMR Shareholding
6 March 2026 11:00
AstraZeneca
-
Total Voting Rights
2 March 2026 15:00
AstraZeneca
-
AstraZeneca prices a $2bn bond offering
26 February 2026 07:00
AstraZeneca
-
Filing of Form 20-F with SEC
25 February 2026 07:00
AstraZeneca
-
Annual Financial Report
24 February 2026 11:00
AstraZeneca
-
Directorate change
24 February 2026 07:00
AstraZeneca
-
Fixed-duration Calquence combo approved in US
20 February 2026 07:00
AstraZeneca
-
Final Results
10 February 2026 07:00
AstraZeneca
-
Update on Saphnelo subcutaneous administration
3 February 2026 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2026. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.